Developmental haemostasis

Paul Monagle; Chris Barnes; Vera Ignjatovic; Janine Furmedge; Fiona Newall; Anthony Chan; Lidia De Rosa; Simone Hamilton; Philip Ragg; Stephen Robinson; Alex Auldist; Cathy Crock; Neil Roy; Shelley Rowlands

doi:10.1160/TH05-01-0047

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(02): 362-372
DOI: 10.1160/TH05-01-0047

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

Developmental haemostasis

Impact for clinical haemostasis laboratories

Authors

Paul Monagle

¹Department of Haematology

⁴Department of Pathology, University of Melbourne, Australia
Chris Barnes

¹Department of Haematology
Vera Ignjatovic

¹Department of Haematology

⁵Murdoch Children’s Research Institute, Melbourne, Australia
Janine Furmedge

¹Department of Haematology
Fiona Newall

¹Department of Haematology
Anthony Chan

⁶Department of Paediatrics, McMaster University, Hamilton, Canada
Lidia De Rosa

¹Department of Haematology
Simone Hamilton

¹Department of Haematology
Philip Ragg

²Department of Anaesthetics
Stephen Robinson

²Department of Anaesthetics
Alex Auldist

³Department of Surgery, Royal Children’s Hospital, Melbourne, Australia
Cathy Crock

¹Department of Haematology
Neil Roy

⁷Department of Neonatology
Shelley Rowlands

⁸Department of Obstetrics, Royal Women’s Hospital, Melbourne, Australia

Abstract

Summary

Developmental haemostasis is a concept, now universally accepted, introduced by Andrew et al. in the late 1980’s. However, coagulation analysers and reagents have changed significantly over the past 15 years. Coagulation testing is known to be sensitive to changes in individual reagents and analysers. We hypothesised that the reference ranges developed by Andrew et al. may not be appropriate for use in a modern coagulation laboratory. Our study was designed to determine whethera current day coagulation testing system (STA Compact analyser and Diagnostica Stago reagent system) was sensitive to agerelated changes in coagulation assays. This is the first large scale study since Andrew et al. to determine the age associated numerical changes in coagulation proteins. Our results confirm the concepts of developmental haemostasis elucidated by Andrew et al. However, our results clearly demonstrate that the absolute values of reference ranges for coagulation assays in neonates and children vary with analyser and reagent systems. The results confirm the need for coagulation laboratories to develop age-related reference ranges specific to their own testing systems. Without this, accurate diagnosis and management of neonates and children with suspected bleeding or clotting disorders is not possible. Finally we present age related reference ranges for D-dimers, TFPI, and endogenous thrombin potential, previously not described.

Keywords

Reference ranges - developmental haemostasis - paediatric

Full Text

References

References
1 Andrew M, Paes B, Milner R. et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-72.
2 Andrew M, Paes B, Milner R. et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72: 1651-7.
3 Andrew M, Vegh P, Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
4 Royston P, Wright E. Goodness-of-fit statistics for age-specific reference intervals. Statist Med 2000; 19: 2943-62.
5 Monagle P, Andrew M. Developmental Hemostasis: Relevance to Newborns and Infants. In: Nathan DG, Oski FA. eds. Hematology of Infancy and Childhood. Vol 1. 6th Edition. Philadelphia, PA: Saunders; 2003: 121-69.
6 Barnes C, Newall F, Harvey S. et al. Interpretation of thrombophilia in childhood stroke; a cautionary tale. J Child Neurol 2004; 19: 218-9.
7 Monagle P, Ignjatovic V, Barnes C. et al. The importance of age appropriate haemostasis reference ranges. Blood 2002; 100: 94-95 (a).
8 Olson J, Arkin C, Brandt J. et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 782-98.
9 Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104.
10 Hirsh J, Raschke R. Heparin and Low Molecular Weight Heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. CHEST 2004; 126: 188S-203S.
11 Laffan MA. Manning RA: Investigation of haemostasis. In: Lewis SM, Bain BJ, Bates I. eds. Dacie and Lewis Practical Haematology. 9th Edition. Churchill Livingstone; 2001: 347-48.
12 Berry L, Andrew M, Post M. et al. A549 lung epithelial cell line synthesize anticoagulant molecules on the cell surface, matrix, and in conditioned media. Am J Resp Cell Mol Biol 1991; 04: 338-46.
13 Jaffe E, Nachman R, Becker C. et al. Culture of human endothelial cells derived from umbilical veins: Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
14 Walenga J, Fareed J. Automation and quality control in the coagulation laboratory. Thromb Haemost 1994; 14: 709-28.
15 White G. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost 2003; 01: 2267-70.
16 Williams N. et al. The STA Haemostasis Analyser - an evaluation. 4^th South Pacific Congress of Medical Scientists. Gold Coast; Australia: 1995
17 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 204S-233S.
18 Monagle P, Andrew MJ. Coagulation abnormalities following Fontan procedures. Thorac Cardiovasc Surg 1998; 115: 732-3.
19 Barnes C, Monagle P. Hemostatic changes following the modified Fontan procedure. Thromb Haemost 2001; 86: 1341-2.
20 Brill-Edwards P, Ginsburg JS, Johnston M. et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9.
21 D’Angelo A, Seveso M, D’Angelo S. et al. Effect of clot-detection methods and reagents on APTT-implications in heparin monitoring by APTT. Am J Clin Path 1990; 94: 297-306.
22 Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
23 Stevenson KJ, Easton AC, Curry A. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. Thromb Haemost 1986; 55: 250-8.
24 Gram J, Declerck P, Sidelmann J. et al. Mulitcentre evaluation of commercial kit methods: plasminogen activator inhibitor activity. Thromb Haemost 1993; 70: 852-7.
25 Declerck P, Moreau H, Jespersen J. et al. Multicentre evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 1993; 70: 858-63.
26 Libeer J-C. Good medical laboratory services - guidelines. Vol. 1, 2nd ed. Dordrecht: Kluwer Academic Publishers BV; 1999
27 Dacie J, Lewis S. Practical Haematology. Vol. 7th . Edinburgh: Churchill Livingstone; 1991
28 Monagle P, Michelson AD, Chan A. et al. Antithrombotic therapy in children. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 645S-687S.
29 Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74: 415-25.
30 Monagle P, Hagstrom JN. Developmental Haemostasis. In: Polin Fox. and Abman, eds. Fetal and Neonatal Physiology. 3rd Edition. Elsevier St: Louis; 2003: 1435-46.
31 Folkman J. Angiogenesis and proteins of the hemostatic system. J Thromb Haemost 2003; 01: 1681-2.
32 Zhang W, Chuang Y, Swanson R. et al. Antiangiogenic antithrombin down regulates the expression of the proangiogenic heparan sulphate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185-91.